Other anti obesity medication
Orlistat
ORLISTAT
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -1.82 (-8.05 to 4.09) | 0.30 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -1.33 (-7.22 to 4.29) | 0.24 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -1.72 (-10.95 to 7.75) | 0.33 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -1.73 (-10.21 to 6.53) | 0.34 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.51 (0.08 to 2.01) | 0.72 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.51 (0.09 to 1.95) | 0.79 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.54 (0.28 to 0.94) | 0.94 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.68 (0.37 to 1.19) | 0.88 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.61 (0.18 to 1.68) | 0.92 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.73 (0.21 to 1.99) | 0.91 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.34 (1.69 to 6.80) | 0.25 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.14 (1.98 to 8.26) | 0.18 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.76 (0.27 to 1.96) | 0.81 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.86 (0.31 to 2.14) | 0.77 |
Trials
- NCT00422058Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period2007 · 564 randomized · 52 weeks
- S0030672007 · 564 randomized · 52 weeks